» Articles » PMID: 30621723

ARNTL Hypermethylation Promotes Tumorigenesis and Inhibits Cisplatin Sensitivity by Activating CDK5 Transcription in Nasopharyngeal Carcinoma

Overview
Publisher Biomed Central
Specialty Oncology
Date 2019 Jan 10
PMID 30621723
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increasing evidence support an important role for DNA methylation in nasopharyngeal carcinoma (NPC). Here, we explored the role of circadian clock gene Aryl Hydrocarbon Receptor Nuclear Translocator-Like (ARNTL) methylation in NPC.

Methods: We employed bisulfite pyrosequencing to determine the epigenetic change of ARNTL in NPC cell lines and tissues. ARNTL mRNA and protein expression in cell lines and tissues were detected by real-time PCR and western blotting. Then, we constructed cell lines overexpressing ARNTL and knocked down ARNTL to explore its function and effect on chemotherapy sensitivity of NPC cell lines to cisplatin in vitro and vivo. Finally, we investigated the potential molecular mechanism of ARNTL by gene set enrichment analysis (GSEA), dual Luciferase reporter assay and chromatin immunoprecipitation assay.

Results: ARNTL was hypermethylated, and its mRNA and protein were significantly down-regulated in NPC cell lines and tissues. When treated by 5-aza-2'-deoxycytidine, mRNA expression was up-regulated. Overexpression of ARNTL could suppress NPC cells proliferation in vitro and vivo while silencing of ARNTL using shRNA achieved opposite results. GSEA assay found that ARNTL was associated with cell cycle and ectopic ARNTL overexpression could induce G2-M phase arrest. Then, we identified and validated cyclin-dependent kinase 5 (CDK5) as the targeting gene of ARNTL by dual Luciferase reporter assay and chromatin immunoprecipitation assay. When transiently infected ARNTL-overexpression cells with PENTER-vector or PENTER-CDK5 plasmids, the later could reverse the suppressive effects of ARNTL on NPC cell proliferation. Moreover, ARNTL significantly enhanced sensitivity to cisplatin in NPC cells.

Conclusions: ARNTL suppresses NPC cell proliferation and enhances sensitivity to cisplatin by targeting CDK5. ARNTL may represent a novel therapeutic target for NPC.

Citing Articles

The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.

Wang J, Shao F, Yu Q, Ye L, Wusiman D, Wu R Research (Wash D C). 2025; 8:0612.

PMID: 40046513 PMC: 11880593. DOI: 10.34133/research.0612.


Role of N6-methyladenosine methylation in nasopharyngeal carcinoma: current insights and future prospective.

Zhao Y, Li J, Dian M, Bie Y, Peng Z, Zhou Y Cell Death Discov. 2024; 10(1):490.

PMID: 39695216 PMC: 11655975. DOI: 10.1038/s41420-024-02266-y.


Impact of Modern Lifestyle on Circadian Health and Its Contribution to Adipogenesis and Cancer Risk.

Dobrovinskaya O, Alamilla J, Olivas-Aguirre M Cancers (Basel). 2024; 16(21).

PMID: 39518143 PMC: 11545514. DOI: 10.3390/cancers16213706.


Hepatocellular Carcinoma in Mice Affects Neuronal Activity and Glia Cells in the Suprachiasmatic Nucleus.

Yassine M, Hassan S, Yucel L, Purath F, Korf H, von Gall C Biomedicines. 2024; 12(10).

PMID: 39457515 PMC: 11504045. DOI: 10.3390/biomedicines12102202.


Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling.

Wang J, Jia Q, Sun J, Wu S, Wei L, Yao W Cancer Biol Ther. 2024; 25(1):2408042.

PMID: 39341782 PMC: 11445925. DOI: 10.1080/15384047.2024.2408042.


References
1.
Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

2.
Lai S, Li W, Chen L, Luo W, Chen Y, Liu L . How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?. Int J Radiat Oncol Biol Phys. 2010; 80(3):661-8. DOI: 10.1016/j.ijrobp.2010.03.024. View

3.
Sun X, Su S, Chen C, Han F, Zhao C, Xiao W . Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2013; 110(3):398-403. DOI: 10.1016/j.radonc.2013.10.020. View

4.
Sun Y, Li W, Chen N, Zhang N, Hu G, Xie F . Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11):1509-1520. DOI: 10.1016/S1470-2045(16)30410-7. View

5.
Esteller M . Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16 Spec No 1:R50-9. DOI: 10.1093/hmg/ddm018. View